Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination
<p>Abstract</p> <p>Background</p> <p>Efficacy of cancer vaccines may be limited due to immune escape mechanisms like loss or mutation of target antigens. Here, we analyzed 10 HLA-A2 positive patients with acute myeloid leukemia (AML) for loss or mutations of the WT1 epi...
Main Authors: | Ochsenreither Sebastian, Nonnenmacher Anika, Scheibenbogen Carmen, Letsch Anne, Busse Antonia, Thiel Eckhard, Keilholz Ulrich |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-01-01
|
Series: | Journal of Translational Medicine |
Online Access: | http://www.translational-medicine.com/content/8/1/5 |
Similar Items
-
Wilms’ Tumor 1 (WT1): The Vaccine for Cancer
by: Kyaw Zaw Hein, et al.
Published: (2020-11-01) -
Design of an Optimized Wilms’ Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo
by: Daphné Benteyn, et al.
Published: (2013-01-01) -
Wilms Tumor-1 (WT1) rs16754 Polymorphism
by: Pathum Sookaromdee, et al.
Published: (2019-02-01) -
Immunoresponse to Wilms Tumor antigen-1 (WT-1) in CML patients.
by: Bellantuono, I, et al.
Published: (2000) -
Implications of the Wilms’ Tumor Suppressor Wt1 in Cardiomyocyte Differentiation
by: Nicole Wagner, et al.
Published: (2021-04-01)